Log in to save to my catalogue

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2310710163

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with
FLT3
mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recovery in 34.0% of patients (vs. 15.3%).

Alternative Titles

Full title

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2310710163

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2310710163

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1902688

How to access this item